By Kingsley Ani
Helios Investment Partners generated approximately $460 million in realised liquidity in 2025 through multiple exits, including the listing of portfolio company T2S Group on the Casablanca Stock Exchange in Morocco. The IPO raised MAD 1.1 billion, about $120 million, valuing T2S at approximately MAD 4.9 billion, or $520 million. The offer was oversubscribed 44 times, while Helios retained a 42 percent stake as T2S’s largest shareholder.
DECISION HIGHLIGHT
The transactions demonstrate how Helios is converting long-term operational restructuring and platform-building into liquidity while retaining exposure to future growth.
DECISION MEMO
The T2S transaction is significant because the value realisation followed four years of operational integration rather than a simple financial exit. Since Helios invested in 2021, four complementary businesses have been combined into one MedTech platform, alongside investment in governance, management, operations, technology and commercial capabilities.
That approach has broadened T2S from medical equipment distribution into an integrated healthcare platform covering manufacturing, digital systems, technical services, maintenance and specialised medical technologies.
The IPO therefore serves two functions. It provides T2S with greater visibility and access to capital for its next growth phase, while giving Helios partial liquidity without relinquishing its strategic exposure through the retained 42 percent stake.
The 44-times oversubscription also indicates substantial investor demand for the company’s public-market offering, although the material provided does not establish whether that demand will translate into sustained post-listing performance.
T2S’s contribution to Morocco’s healthcare ecosystem, including radiopharmaceutical capacity and local engineering and technical capabilities, adds an industrial-development dimension to the transaction. Its ambitions across African markets further position the listing as a potential platform for regional growth.
For Helios, the broader implication is portfolio recycling. Its 2025 realised liquidity of $460 million shows the potential of combining capital with operational transformation to create exit opportunities across Africa’s under-penetrated markets.
DATA BOX
- Helios realised liquidity in 2025: approximately $460m.
- T2S IPO proceeds: MAD 1.1bn, approximately $120m.
- T2S valuation: MAD 4.9bn, approximately $520m.
- IPO oversubscription: 44 times.
- Helios retained stake: 42 percent.
- Helios investment in T2S: 2021.
- Complementary businesses integrated since investment: 4.
- T2S operating history: more than 30 years.
- Helios investing experience: more than 20 years.
- Helios investments span: more than 35 African countries.
WHO WINS / WHO LOSES
T2S gains public-market visibility and access to capital, while Helios realises liquidity and retains significant exposure to future growth. Investors gain access to a listed African MedTech platform. The material does not identify a specific losing party.
POLICY SIGNALS
The transaction highlights the role of capital markets in financing healthcare platforms, strengthening local technical capacity and supporting companies seeking regional African growth.
INVESTOR SIGNAL
The combination of operational integration, IPO liquidity and retained ownership provides a model for private capital recycling. The key consideration is whether T2S can convert its enlarged platform and new capital access into sustained growth.
RISK RADAR
The principal risks are execution during the next growth phase, post-listing performance and the ability to sustain T2S’s integrated operating model across expanding African markets. The source material does not provide financial forecasts or post-IPO performance data.
Kingsley Ani is a journalist who has over the years been covering capital, markets, corporate results, economic and public-interest developments with a focus on clear, factual reporting.
Discover more from StakeBridge Media
Subscribe to get the latest posts sent to your email.